Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Harbin Medical University

China · Asia-Pacific · Silver

#529World rank of 1,038
49.0ICI scoreout of 100
#75National rank, of 169 in China
#157Regional rank, of 343 in Asia-Pacific
675Verified industry works, 2021 to 2025
171Company groups worked with (70 on two or more works)

Harbin Medical University is ranked #529 of 1,038, with Silver standing. Its strongest pillar is durability (97): 29 of its company groups are sustained partners (five or more joint works in three or more of the five years). It is held back most by breadth (3): partners concentrated in a few research fields; and by co-creation (47): 675 verified industry works against about 734 expected for its mix of fields.

Research Collaboration Index 2026: #782 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
47

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 675 verified works against about 734 expected for its fields (0.92 times the expected rate).

Durability20% of the score
97

How much of its industry work sits in sustained partnerships with the same company group. 29 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
50

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 70 company groups on two or more joint works; 29 sustained partnerships.

Breadth20% of the score
3

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (49.0) is the weighted average of the four percentiles. Rank 529 of 1,038 overall; 75 of 169 in China; 157 of 343 in Asia-Pacific. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

4.5%of its 14,948 research works in 2021 to 2025 were co-authored with a verified company
0.92Industry co-authorship rate: 0.92 times what its mix of research fields would predict (675 verified works; about 734 expected)
29sustained partnerships: the same company group on five or more joint works in three or more of the five years

In China

75 of 169 ranked universities in China

  1. #73 Fuzhou University world #515, score 50.4
  2. #74 Southern Medical University world #526, score 49.4
  3. #75 Harbin Medical University world #529, score 49.0
  4. #76 Nanjing Tech University world #540, score 48.5
  5. #77 Guangdong University of Technology world #544, score 48.3

All ranked universities →   Asia-Pacific: 157 of 343 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Strongest sector positions

#114 of 638Pharmaceuticals and Therapeutics347.5 verified works in the sector
Pharmaceuticals and Therapeutics
347.5#114 of 638
Medical Technology and Digital Health
23#273 of 323
Biotechnology and Advanced Therapies
21#202 of 220
Artificial Intelligence
7under 20 works
Chemicals, Process and Resources
2under 20 works
Clean Energy Transition
2under 20 works
Advanced Materials and Nanotechnology
1.5under 20 works
Climate, Environment and Sustainability
1under 20 works
Not in any of the 21 sectors
270counted in the overall index

405 of its 675 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Harbin Medical University co-authored verified work with 171 company groups, consortium papers aside: 70 of them on two or more works, and 29 as sustained partners.

The largest 12 of its 171 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
Jiangsu Hengrui MedicineChinaMedicine785 of 5
BeiGeneChinaMedicine445 of 5
Merck & Co. (MSD)United StatesMedicine365 of 5
RocheSwitzerlandMedicine355 of 5
HUTCHMED (China) LimitedHong KongMedicine355 of 5
Innovent BiologicsChinaMedicine245 of 5
LillyChinaMedicine205 of 5
AstraZenecaUnited KingdomMedicine194 of 5
Junshi BiosciencesChinaMedicine185 of 5
Johnson & JohnsonUnited StatesMedicine17.54 of 5
Betta PharmaceuticalsChinaMedicine175 of 5
PhilipsNetherlandsEngineering154 of 5

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Over time

Verified industry works by year

742021
1382022
109.52023
1602024
193.52025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

17 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07129499 Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas with Jiangsu Famous Medical Technology Co., Ltd., 2025
  • NCT07130955 A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease with Shanghai Golden Leaf MedTec Co. Ltd, 2025
  • NCT07622446 Evaluate the Effectiveness and Safety of the OmniHeart 4.0 Percutaneous Ventricular Assist Device in Providing Hemodynamic Support for Patients Undergoing High-risk Percutaneous Coronary Intervention (PCI). with Shanghai Dynaheart Medtech Co., Ltd., 2024
  • NCT06992687 A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors with Shanghai Huaota Biopharmaceutical Co., Ltd., 2024
  • NCT06449274 RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial with Shanghai Shenqi Medical Technology Co., Ltd, 2024
  • NCT06365502 Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) with Shanghai Shenqi Medical Technology Co., Ltd, 2024

Evidence checked

858 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 359 of 1,217 candidate links were set aside.

Why links were set aside
  • 218 company name not written in the author's affiliation
  • 40 part of a university or public institute's own unit
  • 37 ordinary-word name without a company suffix
  • 25 not an industry organisation
  • 13 excluded after hand audit: A provincial centre for disease control (government)
  • 9 a place or common word that failed its stricter rule
  • 17 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

For your communications

Badges you can use

Silver standing badge

Use the badge with a link to this page.

GRP Partnership Intelligence Platform

Where Harbin Medical University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Harbin Medical University ranks #782 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.